| Recruiting | Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib NCT07428707 | National Heart, Lung, and Blood Institute (NHLBI) | EARLY_Phase 1 |
| Not Yet Recruiting | Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite NCT07024706 | AstraZeneca | Phase 2 |
| Recruiting | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B NCT07221500 | Nurix Therapeutics, Inc. | Phase 2 |
| Recruiting | Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma NCT07030400 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Recruiting | Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL NCT06849713 | Massachusetts General Hospital | Phase 2 |
| Recruiting | A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated W NCT06788639 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | — |
| Enrolling By Invitation | Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR NCT06762431 | Vitebsk Regional Clinical Cancer Centre | Phase 1 / Phase 2 |
| Completed | A Case Crossover Study of Intermittent Fasting in CLL/SLL NCT05708326 | British Columbia Cancer Agency | N/A |
| Terminated | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma NCT05720052 | MingSight Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Recruiting | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022 | Nurix Therapeutics, Inc. | Phase 1 |
| Terminated | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma NCT05144347 | Exelixis | Phase 1 |
| Recruiting | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) NCT05168930 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intraveno NCT05105841 | AbbVie | Phase 2 |
| Recruiting | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137 | Nurix Therapeutics, Inc. | Phase 1 |
| Completed | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T NCT04488354 | Calibr, a division of Scripps Research | Phase 1 |
| Active Not Recruiting | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies NCT04072458 | Bio-Path Holdings, Inc. | Phase 1 |
| Completed | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies NCT04450069 | Calibr, a division of Scripps Research | Phase 1 |
| Active Not Recruiting | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or S NCT04419519 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic NCT03788291 | University of Rochester | Phase 2 |
| Completed | Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Tr NCT03702231 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Unknown | Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignan NCT03588598 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 |
| Completed | A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Dele NCT03406156 | AbbVie | Phase 3 |
| Active Not Recruiting | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma NCT03625037 | Genmab | Phase 1 / Phase 2 |
| Terminated | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML NCT03547115 | MEI Pharma, Inc. | Phase 1 |
| Recruiting | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocyt NCT02966756 | AbbVie | Phase 2 |
| Terminated | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma NCT02914938 | MEI Pharma, Inc. | Phase 1 |
| Completed | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies NCT02362035 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Completed | Study Evaluating Venetoclax in Subjects With Hematological Malignancies NCT02265731 | AbbVie | Phase 1 / Phase 2 |
| Withdrawn | Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (R NCT01754870 | University of Wisconsin, Madison | Phase 2 |
| Completed | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lym NCT01647971 | TG Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL NCT01203930 | Gilead Sciences | Phase 2 |
| Completed | Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic NCT00694590 | Genzyme, a Sanofi Company | Phase 1 |